| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cotzias Neuro-Oncology Laboratory [J. T., R. D., B. B., M. K., R. B.], Departments of Radiology and Medical Physics [C. M., J. K.], and Division of Hematologic Oncology [B. G.], Memorial Sloan-Kettering Cancer Center, New York, New York, and Duke University Medical Center, Durham, North Carolina 27706 [E. G.]
Two aspects of cytokine therapy of intracerebral tumors are considered in this study: modulation of tumor growth in vivo and central nervous system toxicity. Coimplantation of RG-2 glioma cells and retroviral vector producer cell lines was performed to provide a local source of interleukin-2 (IL-2) or IFN-
within the tumor and coinitiate an antitumor immune response. We demonstrated that local intratumoral production of IL-2 and IFN- generates a cell-mediated antitumor response in vivo. This response was manifest as a diffuse infiltration of monocytes/macrophages, CD4+ and CD8+ T cells, and activation of microglial OX42+ cells in intracerebral RG2 tumors. The cell-mediated antitumor immune response resulted in the early suppression of intracranial and subcutaneous tumor growth, but the effect was not sustained and there were no tumor regressions. The absence of increased survival of animals with intracranial tumors is explained in part by the severe central nervous system toxicity caused by local production of IL-2 and IFN-. Central nervous system toxicity included blood-brain barrier disruption, vasogenic brain edema, and dislocation of the brain midline structures, as observed by dynamic magnetic resonance imaging and direct measurements of tissue water content. The clinical application of IL-2 and IFN- gene transfer therapy for intracerebral tumors must consider the potential for severe vasogenic brain edema associated with intracerebral production of these cytokines.
1 To whom requests for reprints should be addressed, at Department of Neurology, K923, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021.
Received 8/ 3/94. Accepted 2/27/95.
This article has been cited by other articles:
|
|
 |
|
  X. Jiang, X. Lu, R. Liu, F. Zhang, and H. Zhao HLA Tetramer Based Artificial Antigen-Presenting Cells Efficiently Stimulate CTLs Specific for Malignant Glioma Clin. Cancer Res., December 15, 2007; 13(24): 7329 - 7334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Kueng, V. M. Leb, D. Haiderer, G. Raposo, C. Thery, S. V. Derdak, K. G. Schmetterer, A. Neunkirchner, C. Sillaber, B. Seed, et al. General Strategy for Decoration of Enveloped Viruses with Functionally Active Lipid-Modified Cytokines J. Virol., August 15, 2007; 81(16): 8666 - 8676. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Prins, S. K. Odesa, and L. M. Liau Immunotherapeutic Targeting of Shared Melanoma-Associated Antigens in a Murine Glioma Model Cancer Res., December 1, 2003; 63(23): 8487 - 8491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Liau, E. R. Jensen, T. J. Kremen, S. K. Odesa, S. N. Sykes, M. C. Soung, J. F. Miller, and J. M. Bronstein Tumor Immunity within the Central Nervous System Stimulated by Recombinant Listeria monocytogenes Vaccination Cancer Res., April 1, 2002; 62(8): 2287 - 2293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Iwadate, A. Yamaura, Y. Sato, S. Sakiyama, and M. Tagawa Induction of Immunity in Peripheral Tissues Combined with Intracerebral Transplantation of Interleukin-2-producing Cells Eliminates Established Brain Tumors Cancer Res., December 1, 2001; 61(24): 8769 - 8774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Graf, R. M. Prins, and R. E. Merchant IL-6 Secretion by a Rat T9 Glioma Clone Induces a Neutrophil-Dependent Antitumor Response with Resultant Cellular, Antiglioma Immunity J. Immunol., January 1, 2001; 166(1): 121 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Graf, M. R. Jadus, J. C. Hiserodt, H. T. Wepsic, and G. A. Granger Development of Systemic Immunity to Glioblastoma Multiforme Using Tumor Cells Genetically Engineered to Express the Membrane-Associated Isoform of Macrophage Colony-Stimulating Factor J. Immunol., November 15, 1999; 163(10): 5544 - 5551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Molnar, I. Fekete, K. E. Schlageter, G. D. Lapin, and D. R. Groothuis Absence of Host-Site Influence on Angiogenesis, Blood Flow, and Permeability in Transplanted RG-2 Gliomas Drug Metab. Dispos., September 1, 1999; 27(9): 1085 - 1091. [Abstract] [Full Text]
|
|
|
|
|
|
S. Benedetti, M. G. Bruzzone, B. Pollo, F. DiMeco, L. Magrassi, B. Pirola, N. Cirenei, M. P. Colombo, and G. Finocchiaro Eradication of Rat Malignant Gliomas by Retroviral-mediated, in Vivo Delivery of the Interleukin 4 Gene Cancer Res., February 1, 1999; 59(3): 645 - 652. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
